Systemic Therapy with or without Local Consolidative Therapy in Treating Patients with Oligometastatic Solid Tumor

Inclusion Criteria

• PRIOR TO CLINICAL ONCOLOGY RESEARCH (CORe) ENROLLMENT: No more than 4 prior lines of systemic therapy administered to treat metastatic disease
• PRIOR TO CLINICAL ONCOLOGY RESEARCH (CORe) ENROLLMENT: Be >= 18 years of age on the day of signing informed consent
• PRIOR TO CLINICAL ONCOLOGY RESEARCH (CORe) ENROLLMENT: Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• PRIOR TO CLINICAL ONCOLOGY RESEARCH (CORe) ENROLLMENT: Pathologically confirmed diagnosis of cancer
• FOLLOWING CORe ENROLLMENT: Oligometastatic solid tumors patients (=< 5 metastatic lesions at the time of study entry)
• FOLLOWING CORe ENROLLMENT: Candidate for definitive local therapy to all sites of active disease per the discretion of the treating physicians
• FOLLOWING CORe ENROLLMENT: Absolute neutrophil count (ANC) >= 500/mcL (performed within 6 weeks prior to study enrollment)
• FOLLOWING CORe ENROLLMENT: Platelets >= 25,000/mcL (performed within 6 weeks prior to study enrollment)
• FOLLOWING CORe ENROLLMENT: Hemoglobin >= 7 g/dL (performed within 6 weeks prior to study enrollment)
• FOLLOWING CORe ENROLLMENT: Serum total bilirubin =< 1.5 mg/dl (except for subjects with Gilbert syndrome, who may have total bilirubin < 3.0 mg/dl) OR direct bilirubin =< upper limit normal (ULN) for subjects with total bilirubin levels > 1.5 mg/dl (performed within 6 weeks prior to study enrollment)
• FOLLOWING CORe ENROLLMENT: Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) =< 3 X ULN OR =< 5 X ULN for subjects with liver metastases (performed within 6 weeks prior to study enrollment)

Exclusion Criteria

• PRIOR TO CORe ENROLLMENT: Has a diagnosis of active scleroderma, lupus, or other rheumatologic disease which in the opinion of the treating radiation oncologist precludes safe radiation therapy
• PRIOR TO CORe ENROLLMENT: Is cognitively-impaired or has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
• PRIOR TO CORe ENROLLMENT: Additional diagnosis of another primary malignancy outside of the malignancy being treated on trial that per the discretion of the treating physicians and investigational team offers a substantial risk to the patient’s life (e.g. primary lung cancer definitively treated in the past 6 months would offer a significant risk to the patient’s life, while a basal cell carcinoma treated with local excision would not)
• FOLLOWING CORe ENROLLMENT: Metastatic effusion (e.g. pleural effusion or ascites). Note that patients with an effusion that is too small to sample will be eligible for the trial
• FOLLOWING CORe ENROLLMENT: Diffuse metastatic processes including leptomeningeal disease, diffuse bone marrow involvement, and peritoneal carcinomatous, which by the discretion of the treating physician cannot be treated definitively
• FOLLOWING CORe ENROLLMENT: Is pregnant or expecting to conceive within the projected duration of the trial at the screening visit * Female subject of childbearing potential should have a negative urine or serum pregnancy within 6 weeks prior to study registration up to the first fraction of radiation * Note: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required